Recent News

Movado Group Rises More Than 9% Premarket After Posting Q1 Adjusted EPS

Movado Group Rises More Than 9% Premarket After Posting Q1 Adjusted EPS

Shares of Movado Group (MOV), the Swiss watchmaking company, rose more than 9% in premarket trade after it posted Q1 adjusted EPS of $0.37 compared with $0.01 a year earlier and beating the $0.11 average estimate by analysts in a Capital IQ poll. Net sales in the quarter ended April 30 increased 28.1% to $127.1 million from $99.3 million a […]

Titan Pharmaceuticals, Braeburn End License Agreement For Probuphine For Opioid Dependence

Titan Pharmaceuticals, Braeburn End License Agreement For Probuphine For Opioid Dependence

Titan Pharmaceuticals (TTNP) and pharmaceutical company Braeburn have agreed to terminate a license agreement that granted Braeburn exclusive rights to commercialize Probuphine, an opioid addiction treatment, in the US and Canada. Probuphine is a subdermal implant designed to deliver buprenorphine, an opioid used to treat opioid dependence, continuously for six months following a single treatment. Under the terms of the […]

GasLog LP Secures Time Charter Contract for Newbuild LNG Carrier

GasLog LP Secures Time Charter Contract for Newbuild LNG Carrier

GasLog LP (GLOG), an operator of liquid natural gas carriers, said Wednesday it has signed a seven-year time charter contract with Centrica plc for a newbuild LNG carrier. The 180,000 cubic meter LNG carrier (HN 2262) with low pressure two stroke propulsion has been ordered from Samsung Heavy Industries in South Korea, with expected delivery in Q3 2020. GasLog and […]

Celgene to Present Data From More Than 60 Cancer Therapy Studies

Celgene to Present Data From More Than 60 Cancer Therapy Studies

Celgene (CELG), the biotechnology company, said that data from more than 60 company-sponsored, cooperative group and investigator-initiated clinical studies evaluating its experimental therapies will be presented at the American Society of Clinical Oncology Annual Meeting between June 1-5 in Chicago. “Cancer research is at a critical point where advances in cellular immunotherapy may be able to drive previously unattainable advancements,” […]

Axon Enterprise Prices Offering of 4.3 Mln Shares at $53 Per Share

Axon Enterprise Prices Offering of 4.3 Mln Shares at $53 Per Share

Axon Enterprise (AAXN) said late Wednesday it priced an offering of 4.3 million common shares, 4 million of which will come from the company and 300,000 from CEO Patrick Smith, at $53 apiece. The company has granted underwriters a 30-day option to buy up to an additional 645,000 shares. Net proceeds will be used for working capital and other general […]

Loxo Oncology Gains More Than 14.5%

Loxo Oncology Gains More Than 14.5%

Loxo Oncology (LOXO) jumped more than 14.5% after the company said study investigators will present interim data from the ongoing Phase 1 clinical trial for LOXO-292 in oral and poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting. The submitted abstract utilized a January 2018 data cut-off date. The presentation at the ASCO Annual Meeting will use […]

Jounce Therapeutics Plunges More Than 27.5%

Jounce Therapeutics Plunges More Than 27.5%

Jounce Therapeutics (JNCE) slid more than 27.5% after the company said data from its ongoing Phase 1/2 ICONIC trial, an adaptive design, open label trial evaluating JTX-2011 monotherapy and in combination with nivolumab, will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. It said it met its target enrollment for the Phase 1/2 ICONIC […]